Please assess the completion status of the following clinical trial:

Trial Title: Effects of Testosterone in Women With Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female, age 18-75~* Written informed consent~* Meet Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria (by Structured Clinical Interview for DSM-IV (SCID)) for Major Depressive Disorder~* Meet DSM-IV criteria for a current major depressive episode, as assessed by SCID~* Montgomery-Asberg Depression Rating Scale (MADRS) greater than or equal to 16 at baseline visit~* Currently treated with SSRI or SNRI, with or without adjunctive therapy, at an adequate dose (see adequate dose table below) for at least six weeks~Exclusion Criteria:~* Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy)~* Serious suicide or homicide risk, as assessed by evaluating clinician~* Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic (including uncontrolled seizure disorder)~* Substance use disorder active within last six months~* Psychotic features (current episode or lifetime), as assessed by SCID~* Laboratory evidence of untreated hypothyroidism~* If treated hypothyroidism, significant change in levo-thyroxine dose within the prior three months~* If receiving oral estrogen therapy, including oral contraceptives or transdermal estrogen therapy, significant change in dose in the prior three months~* Use of androgens or androgen precursors, including testosterone, Dehydroepiandrosterone (DHEA) and methyltestosterone, within the prior three months~* Any investigational psychotropic drug within the last two weeks~* In the judgment of the study clinician, unlikely to be able to participate safely throughout the study period (three or more episodes of self-harm in the past year, documented history of poor treatment adherence, or frequent missed appointments (greater than 50%) in the past year)~* Alanine aminotransferase (ALT) greater than 1.5 times the upper limit of normal.~* Creatinine greater than 1.5 times upper limit of normal~* History of a hormone-responsive cancer~* History of congestive heart failure~* MADRS greater than 31

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Testosterone (Type: ACTIVE_COMPARATOR): Testosterone patch delivering 300mcg daily for 8-weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).